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Mutations in the adenomatous polyposis coli (APC) tumour
suppressor gene give rise to familial adenomatous polyposis and
initiate the many, perhaps even majority of sporadic colon cancers
(reviewed by Kinzler and Vogelstein, 1996). The observation that
several copies of a 20-aminoacid repeat sequence in the central
portion of the APC protein specifically associate with b-catenin was
the first important clue in understanding the tumour-suppressive
function of APC (Rubinfeld et al, 1993; Su et al, 1993). A quater-
nary cytoplasmic complex comprising APC, b-catenin, glycogen
sythase kinase 3 b (GSK3 b) and axin leads to b-catenin phosphory-
lation by GSK3 b and, as a consequence, b-catenin is targeted 
for proteasomal destruction by ubiquitination (Hart et al, 1998;
Nakamura et al, 1998). In colon carcinoma (Korinek et al, 1997;
Morin et al, 1997) and melanoma cell lines (Rubinfeld et al, 
1997), the nuclear accumulation of b-catenin caused by mutations in
APC or b-catenin activate the transcription factor, T cell factor-
4/lymphoid enhancer factor-1 (Tcf-4/Lef-1), thereby stimulating cell
proliferation or inhibiting apoptosis. Thus the APC/b-catenin
signaling pathway has been described to play a critical role in
colorectal tumorigenesis (Korinek et al, 1997; Morin et al, 1997;
Sparks et al, 1998). In addition, some studies have suggested the
potential involvement of the Wnt-1 or APC/ b-catenin pathway in
human breast cancers (Dale et al, 1996; Bui et al, 1997; Jonsson 
et al, 2000; Lin et al, 2000; Schlosshauer et al, 2000). 
Recently, it has become apparent that tumour suppressor genes
may be inactivated by aberrant DNA methylation of CpG islands
in their promoter regions, including the p16 (Herman et al, 1995;
Gonzalgo et al, 1997), E-cadherin (Graff et al, 1995; Tamura et al,
2000), BRCAI (Mancini et al, 1998; Rice et al, 1998; Esteller et al,
2000a) and hMLH1 (Kuismanen et al, 2000) genes. Altered DNA
methylation in the p16 (Herman et al, 1995), E-cadherin (Graff et
al, 1995) and BRCAI genes (Mancini et al, 1998; Rice et al, 1998;
Esteller et al, 2000a) has also been reported in breast cancers. In
addition, APC promoter CpG island hypermethylation has been
reported in colorectal (Hiltunen et al, 1997; Esteller et al, 2000b)
and gastric cancers (Tsuchiya et al, 2000). Somatic mutations in
APC have been reported only in 6% of primary breast cancers
(Kashiwaba et al, 1994), despite frequent loss of heterozygosity
(LOH) at the APC locus (Thompson et al, 1993; Medeiros et al,
1994; Kashiwaba et al, 1994) as well as frequent loss of APC
protein expression (Ho et al, 1999). Therefore, we hypothesized
that APC might be inactivated through promoter hypermethylation
in primary breast cancers. 
In order to test this hypothesis, we investigated the methylation
status of APC gene promoter 1A (Esteller et al, 2000b; Tsuchiya et
al, 2000) in DNAs from 50 breast cancers, as well as from 21 non-
tumorous breast tissues by using the methylation-specific PCR
(MSP) method. We also studied mutations of APC and b-catenin
genes using PCR-single-stranded conformational polymorphism
(SSCP) technique. 
MATERIALS AND METHODS 
Samples 
50 cases of primary breast cancer surgically treated at the
Department of Surgery, Iwate Medical University School of
Medicine were included in this study (fresh non-tumorous tissue
was not available for 29 cases). These tumors had been previously
characterized for their stage, ER (oestrogen receptor) and PGR
(progesterone receptor) using the EIA kits from Abbott
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histology according to the histological classification of breast
tumours of the Japanese Breast Cancer Society (1998). The
samples were immediately frozen in liquid nitrogen after 
resection and stored at –80˚C until processing. The tumour and
normal tissue samples were histologically confirmed. Genomic
DNA was extracted using standard procedures (Sambrook et al,
1989). 
Methylation analysis 
Genomic DNA extracted from 50 tumours and 21 non-tumorous
samples was treated with sodium bisulfite as described previously
(Clark et al, 1994). Two published primer-sets specific to
sequences that correspond to either methylated or unmethylated
DNA sequences of APC gene promoter 1A were used (Esteller et
al, 2000b): (a) Mf 5¢-TATTGCGGAGTGCGGGTC-3¢ and Mr 5¢-
TCGACGAACTCCCGACGA-3¢ for methylated DNA sequences
of APC promoter; (b) UMf 5¢-GTGTTTTATTGTGGAGT-
GTGGGTT-3¢ and Umr 5¢-CCAATCAACAAACTCCCAACAA-
3¢ for unmethylated DNA sequences of APC promoter. Briefly,
modified DNAs were amplified in a total volume of 20 ul 1 ´
GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City,
CA) containing 1.0 mM MgCl2, 1 mM each primer, 0.2 mMm
dNTPs, and 1 unit Taq polymerase (AmpliTaq Gold DNA
Polymerase, PE Applied Biosystems). After initial denaturation at
95˚C for 10 min, PCR was performed with 35 cycles consisting of
denaturation at 95˚C for 15 second, annealing 60˚C for 15 second,
and extension at 72˚C for 30 second, followed by a final 7 min
extension step at 72˚C for two primer-sets. PCR products were
then loaded onto non-denaturating 6% polyacrylamide gel, stained
with ethidium bromide, and visualized under UV illumination. In
addition, 100 mg of peripheral blood DNA as a positive control
was treated according to the manufacturer’s protocol (New
England BioLabs, Inc., Beverly, MA) by Sss I Methylase. Sss I-
treated DNA was modified by sodium bisulfite, amplified and
electrophoresed as described above. 
DNA-sequencing analysis 
The methylated and/or unmethylated MSP bands from 5 different
tumours and 3 normal tissues were excised from gels and
subjected to a second round of PCR amplification with the use of
the same primers as used in the primary PCR. These PCR products
were purified and sequenced using the dRhodamine Terminator
Cycle Sequencing FS Ready Reaction Kit (PE Applied
Biosystems) and an automated DNA sequencer (ABI PRISM 310,
PE Applied Biosystems). 
Mutations analysis 
PCR-SSCP analyses for codons 998–1141 and 1260–1547 of the
APC gene, and exon 3 of the b-catenin gene were performed using
published primer sequences and conditions (Kashiwaba et al,
1994; Park et al, 1999). 
Statistical analysis 
Student’s t-test and Fisher’s exact probability test were performed
for statistical analysis. A P value of less than 0.05 was considered
statistically significant. 
RESULTS 
Hypermethylation of APC promoter CpG islands was detected in
18 of 50 (36%) breast cancers. Unmethylated APC alleles were
also present in all the 50 carcinomas (Figure 1A for representative
results). In contrast, only unmethylated APC alleles were detected
in the 21 corresponding non-cancerous breast tissues despite the
presence of methylated APC alleles in 4 (20%) of their cancerous
lesions (Figure 1B). The methylated and/or unmethylated MSP
bands from 5 different tumours and 3 normal tissues were directly
sequenced; the CpG islands in methylated band were always
methylated (Figure 2A for representative results), while the CpG
islands in unmethylated band were always unmethylated 
(Figure 2B). Neither APC nor b-catenin mutations were identified
in any of the tumours by PCR-SSCP. There were no significant
associations between APC promoter hypermethylation and patient
age, stage, size or histological type of the tumour, lymph 
node metastasis, oestrogen or progesterone receptor status 
(Table 1). 
DISCUSSION 
Our results demonstrate that APC promoter CpG island hyperme-
thylation occurs frequently in primary breast cancers. The rate of
hypermethylation of the APC promoter in our study (36%) is
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Figure 1 Methylation analysis of APC promoter region in breast cancers.
(A) methylated alleles are present in case 34 and 42, and only unmethylated
alleles are seen in case 31 and 38 in their cancerous lesions; 
(B) methylated alleles are observed in the cancerous lesions but not in their
corresponding non-cancerous tissues in case 76 and 82. T = cancerous
lesion; N = non-cancerous tissue; M = methylated PCR products; 
U = unmethylated PCR products; P = positive control; D.W. = negative
control; SM = size marker 
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Figure 2 Sequencing analysis of methylated and unmethylated APC
alleles. (A) All CpG sites were methylated in the cancerous lesion of case 76;
B, all CpG sites were unmethylated in the corresponding non-cancerous
tissue of case 76, resulting in the sequence ‘TpG’ after bisulfite treatment similar to the rate of reduction of APC expression in a previous
immunohistochemical study (40%) (Ho et al, 1999), which may
explain the imbalance between LOH at the APC locus, APC protein
expression and APC mutations (Thompson et al, 1993; Kashiwaba
et al, 1994; Medeiros et al, 1994; Ho et al, 1999) in primary breast
cancers. LOH studies have identified 5q, the region which includes
the APC gene, as the site of loss in breast cancers, suggesting a
possible role for APC in the progression of breast cancers
(Thompson et al, 1993; Kashiwaba et al, 1994; Medeiros et al,
1994; Ho et al, 1999). It remains to be seen whether the hyperme-
thylation we observed is associated with the silencing of gene
expression; however, there are numerous examples in the literature
of promoter hypermethylation strongly suppresses gene activity
(Graff et al, 1995; Herman et al, 1995; Mancini et al, 1998; Rice et
al, 1998; Esteller et al, 2000a, b; Kuismanen et al, 2000; Tamura et
al, 2000; Tsuchiya et al, 2000). Among these reports, Esteller et al
(Esteller et al, 2000b) demonstrated that APC promoter hyperme-
thylation is biased toward tumours with genetically intact APC and
associated with transcriptional silencing in colorectal cancers.
Although  APC promoter hypermethylation was previously detected
in only one of 19 (5%) primary breast cancers (Esteller et al, 2000b)
which was less frequent than our present data, this difference might
be derived from difference of race or MSP sensitivity. It is also
possible that it might simply reflect the difference of samples
analysed. Our findings indicate that hypermethylation of APC
promoter CpG islands may be a more common mechanism of inac-
tivation of this tumour suppressor gene in primary breast cancers. 
In breast cancers, the frequent LOH at the APC locus on chromo-
some 5q21 combined with the loss of APC protein expression
(Thompson et al, 1993; Kashiwaba et al, 1994; Medeiros et al, 1994;
Ho et al, 1999) and infrequent somatic mutations of the APC gene
(Kashiwaba et al, 1994) are not suitable for the classic two-hit inacti-
vation mechanism. In this context, Jones and Laird (Jones and Laird,
1999) set forth a new mechanism proposing that aberrant methylation
of a promoter may be a ‘second hit’ accompanied with LOH or muta-
tion for tumour suppressor gene inactivation. In recent studies in
colorectal cancers, Esteller et al (Esteller et al, 2000b) demonstrated
that both alleles of APC are functionally lost, one being deleted and
the other methylated, as shown for the VHL gene in renal cell carci-
noma (Herman et al, 1994), the RBI gene in retinoblastoma (reviewed
by Jones and Laird, 1999), the p16gene in melanoma (Gonzalgo et al,
1997), and the BRCA1 gene in breast cancer (Esteller et al, 2000a). In
our study, hypermethylation of the APC promoter was detected in 18
of 50 (36%) of the breast cancers which was similar to the rate (38%)
of the LOH study by Kashiwaba et al (Kashiwaba et al, 1994), and no
mutations were found. We speculate that the rarity of observed
APC hypermethylation in breast cancer 71
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Table 1 Clinicopathological characteristics and methylation status of APC in breast cancers 
Number of tumours Methylated status 
Methylated Unmethylated 
Age (years) 
%40 6 2 4 
>40 40 15 25 
Unknown 4 1 3 
Stage 
I1 0 6 4  
II 26 7 19 
III 9 4 5 
IV 1 0 1 
Unknown 4 1 3 
Histological type 
Invasive ductal carcinoma 42 17 25 
Papillotubular carcinoma 13 4 9 
Solid-tubular carcinoma 5 2 3 
Scirrhous carcinoma 24 11 13 
Noninvasive ductal carcinoma 1 0 1 
Mucinous carcinoma 2 0 2 
Invasive lobular carcinoma 1 0 1 
Unknown 4 1 3 
Tumour size 
%2.0 cm 17 7 10 
>2.0 %5.0 cm 20 7 13 
>5.0 cm 8 2 6 
Unknown 5 2 3 
Lymph node metastasis 
Positive 26 9 17 
Negative 20 8 12 
Unknown 4 1 3 
Oestrogen receptor status 
Positive 25 8 17 
Negative 20 9 11 
Unknown 5 1 4 
Progesterone receptor status 
Positive 18 4 14 
Negative 26 11 15 
Unknown 6 3 3 somatic mutations of APC is due to the greater likelihood of APC
inactivation by methylation in breast cancers. 
In previous studies of colorectal and gastric cancers, methyla-
tion of the promoter CpG islands of APC was observed in
cancerous as well as non-cancerous tissues (Hiltunen et al, 1997;
Tsuchiya et al, 2000). Our study is the first to show that methyla-
tion of the promoter CpG island of APC occur specifically in
breast cancers but not in their corresponding non-cancerous breast
tissues. In addition, it has been shown that promoter CpG island
methylation is related to aging in several genes, including the ER
gene, the insulin-like growth-factor-II gene  (IGF2) and others
(reviewed by Issa, 2000). However, in our study, methylation of
APC in breast cancers was not associated with the patient’s age.
Thus, hypermethylation of promoter CpG islands of APC is a
cancer-specific change in the breast. 
In the present study, we confirmed the findings of previous
studies (Kashiwaba et al, 1994; Candidus et al, 1996; Jonsson et al,
2000; Schlosshauer et al, 2000) that the mutations of APC and/or
b-catenin are infrequent in primary breast cancers. None of these
studies analysed APC promoter CpG islands hypermethylation in
the same samples, although some studies have indicated the poten-
tial involvement of the APC/b-catenin pathway in human breast
cancers (Jonsson et al, 2000; Lin et al, 2000; Schlosshauer et al,
2000). In our series, no mutations in the APC and b-catenin genes
were found, and APC promoter CpG islands hypermethylation
was identified in 36% of breast cancers. Therefore, it is likely that
methylation of APC gene may disrupt the regulation in the APC/b-
catenin pathway in breast cancers. 
In conclusion, hypermethylation of APC promoter CpG islands
is a cancer-specific change, and may be a more common mecha-
nism of inactivation of this tumour suppressor gene in primary
breast cancers than previously thought. 
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